Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem Cells

Nanfang Hospital, Southern Medical University

Status: Unknown

Conditions: Chronic Myeloid Leukemia

Study type: Observational

Funder types: Other

Identifiers

NCT04991532

NFEC-2021-130

Details and patient eligibility

About

Research on the mechanism of dasatinib down-regulates the expression of PD-1 in CMV-activated NKG2C+NK cells and enhances killing pH + leukemia stem cells.

Full description

Some patients with CML can withdraw from TKIs after treatment, and the mechanism might be related to the effect of memory NK cells on anti-Ph+ leukemic stem cells (LSCs). Dasatinib affects immune through several pathways including the expression of PD1 in immune cells. Our previous work showed increased NKG2C+ NK cells were found in cases with CMV-DNA+ who suffered Ph+ leukemia and received Dasatinib, and these memory NK cells have anti-LSCs activity. We hypothesize that: CMV infection activates NKG2C+ memory NK cells proliferation; Dasatinib down-regulates the expression of PD1 in PD1+NKG2C+ NK cell subsets and then enhances anti-LSCs activity of these cells. In this study, the effect of Dasatinib on CMV-activated NKG2C+ cell subsets and its mechanism will be studies. Besides, the different NKG2C+ cell subsets on LSCs will be compared. This study might be helpful to clarify the mechanism of TKI withdrawal and to offer foundation for CMV and Ph+ ALL treatment strategies

Enrollment: 324 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age >18 years old, gender is not limited
2. CML-CP patients treated with TKIs
3. No pregnancy was planned during the treatment

Exclusion criteria

1.The researcher judged that it was not suitable to participate in this study

Trial design

324 participants in 2 patient groups

Dasatinib group

Description:

the CML patient treated with dasatinib

Imatinib group

Description:

the CML patient treated with imatinib